Todd Asset Management LLC Has $725,000 Stake in Johnson & Johnson (JNJ)
Todd Asset Management LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 2.1% during the second quarter, Holdings Channel reports. The firm owned 5,973 shares of the company’s stock after buying an additional 120 shares during the period. Todd Asset Management LLC’s holdings in Johnson & Johnson were worth $725,000 as of its most recent filing with the SEC.
Other hedge funds have also recently added to or reduced their stakes in the company. Americafirst Capital Management LLC bought a new position in Johnson & Johnson during the second quarter valued at approximately $101,000. INR Advisory Services LLC bought a new position in Johnson & Johnson during the second quarter valued at approximately $150,000. Capital Asset Advisory Services LLC bought a new position in Johnson & Johnson during the second quarter valued at approximately $202,000. NewSquare Capital LLC boosted its position in Johnson & Johnson by 4.9% in the second quarter. NewSquare Capital LLC now owns 1,791 shares of the company’s stock valued at $217,000 after buying an additional 83 shares during the last quarter. Finally, Shayne & CO. LLC bought a new position in Johnson & Johnson during the second quarter valued at approximately $219,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson (NYSE:JNJ) traded down 0.1148% during trading on Wednesday, hitting $118.6836. 2,744,764 shares of the stock were exchanged. The firm’s 50 day moving average price is $119.00 and its 200-day moving average price is $116.96. Johnson & Johnson has a 1-year low of $93.44 and a 1-year high of $126.07. The stock has a market cap of $324.70 billion, a price-to-earnings ratio of 22.1177 and a beta of 0.62.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The business earned $18.50 billion during the quarter, compared to analyst estimates of $17.98 billion. On average, analysts anticipate that Johnson & Johnson will post $6.69 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were given a $0.80 dividend. The ex-dividend date of this dividend was Friday, August 19th. This represents a $3.20 annualized dividend and a dividend yield of 2.69%. Johnson & Johnson’s dividend payout ratio is presently 60.15%.
JNJ has been the topic of several research analyst reports. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 target price on the stock in a research note on Monday, August 22nd. Barclays PLC reissued an “overweight” rating and set a $125.00 target price (up previously from $120.00) on shares of Johnson & Johnson in a research note on Sunday, July 10th. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 target price on the stock in a research note on Friday, August 5th. BTIG Research restated a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, September 7th. Finally, Jefferies Group raised their price objective on shares of Johnson & Johnson from $109.00 to $113.00 and gave the company a “hold” rating in a research report on Thursday, July 14th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $120.19.
In related news, VP Dominic J. Caruso sold 41,146 shares of the business’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total value of $5,143,661.46. Following the completion of the transaction, the vice president now directly owns 157,819 shares in the company, valued at approximately $19,728,953.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Ronald A. Kapusta sold 2,935 shares of the business’s stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total value of $366,904.35. Following the completion of the transaction, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at $3,582,786.60. The disclosure for this sale can be found here. 0.11% of the stock is owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.